Abstract 2347P
Background
Many survivors of first primary cancers (FPCs) are at risk of developing a second primary cancer (SPC), the development of which usually leads to a worse prognosis. The development of SPCs may be closely related to the FPC. Different primary cancers have differentially high frequencies of specific SPC development. Our aim was to explore the possible correlation between the SPCs and FPCs.
Methods
We retrospectively searched and screened relevant literature on SPCs from four databases, namely, PubMed, EMBASE, Web of Science, and PMC. We also collected data on 28 different organ sites and the number of patients with SPC from The Surveillance, Epidemiology, and End Results (SEER) 8 Registry Database and NHANES database.
Results
A total of 9,617,643 patients with a FPC and 677,430 patients with a SPC were included in this meta-analysis. Patients with first primary gynaecological cancer and thyroid cancer developed second primary breast cancer and colorectal cancer more frequently. Patients with first primary head and neck cancer, anal cancer and esophageal cancer developed second primary lung cancer more frequently. Patients with first primary bladder cancer and penile cancer developed second primary lung cancer and prostate cancer more frequently. Patients with second primary bladder cancer accounted for 56% of first primary ureteral cancer patients with SPCs.
Conclusions
We recommend close clinical follow-up, monitoring and appropriate interventions in patients with relevant FPCs for better screening and early diagnosis of SPCs to prolong patient survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peng Luo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2346P - Spatial and quantified molecular characterization of high endothelial venule predictive of immunotherapy response
Presenter: Kunheng Du
Session: Poster session 16
2348P - High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma
Presenter: hongfang zhang
Session: Poster session 16
2349P - Patterns and frequency of pathogenic germline variants (PGVs) among non-western young male patients with cancer: The Jordanian exploratory cancer genetics (Jo-ECAG) study
Presenter: Hira Bani Hani
Session: Poster session 16
2350P - Single-cell RNA-seq dissecting the initiating liver metastasis cells in various cancers
Presenter: Shu-yue Zheng
Session: Poster session 16
2351P - Whole genome sequencing of AYA patients
Presenter: Paul Roepman
Session: Poster session 16
2352P - Sex-based differences in genomic alterations and biomarkers in anal squamous cell carcinoma (ASCC)
Presenter: Stefano Cereda
Session: Poster session 16
2353P - Anti-cancer effects of HDAC8 specific inhibitors EC-352H and EC-374H in lymphoma
Presenter: So Young Lee
Session: Poster session 16
2354P - Computational pathology-derived features capture varied epithelial-mesenchymal transition (EMT) states
Presenter: Herbert Levine
Session: Poster session 16
2355P - Carcinoembryonic antigen (CEA) expression in human tumors: A tissue microarray study on 15,413 tumors
Presenter: Kristina Jansen
Session: Poster session 16
2356P - The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC
Presenter: Arianna Marinello
Session: Poster session 16